Ligand id: 9737

Name: M5717

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 57.7
Molecular weight 462.24
XLogP 3.43
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A first-in-human Phase I clinical trial of M5717 has been completed (NCT03261401, last update June, 2019).
Mechanism Of Action and Pharmacodynamic Effects
M5717 inhibits P. falciparum protein synthesis, with evidence from genetic experiments indicating P. falciparum elongation factor 2 (PfeEF2) may be the molecular target [1]. eEF2 catalyzes the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis in eukaryotes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03261401 First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Subjects Phase 1 Interventional Merck KGaA, Darmstadt, Germany